CytoDyn Inc.

CYDY

US23283M1018

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 01:26:11 18/07/2024 am IST			5-day change	1st Jan Change
0.1408 ^USD	-1.95%		+0.64%	-27.79%

27/06	CytoDyn Inc. and SMC Laboratories, Inc. Announce Start of Preclinical MASH Study	CI
30/05	Transcript : CytoDyn Inc. - Special Call

CytoDyn Inc. announced that it has received $0.88 million in funding

January 10, 2018

On January 10, 2018, CytoDyn Inc. (OTCPK:CYDY) closed the transaction.

Latest news about CytoDyn Inc.

CytoDyn Inc. and SMC Laboratories, Inc. Announce Start of Preclinical MASH Study	27/06	CI
Transcript : CytoDyn Inc. - Special Call	31/05
CytoDyn Inc. announced that it has received $8.942 million in funding	03/05	CI
CytoDyn Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	16/04	CI
Transcript : CytoDyn Inc. - Special Call	05/03
CytoDyn Inc. Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma	01/02	CI
Cytodyn Inc. Announces CFO Changes	29/01	CI
CytoDyn Inc. Announces Appointment of Jacob Lalezari as CEO	29/01	CI
CytoDyn Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	17/01	CI
CytoDyn Inc. announced a financing transaction	29/12	CI
Transcript : CytoDyn Inc. - Special Call	15/12
CytoDyn Inc. Appoints Jacob Lalezari M.D. as Interim CEO	21/11	CI
CytoDyn Inc. Reports Earnings Results for the First Quarter Ended August 31, 2023	24/23/24	CI
CytoDyn Inc. Reports Earnings Results for the Full Year Ended May 31, 2023	14/23/14	CI
Transcript : CytoDyn Inc. - Special Call	25/23/25
CytoDyn Inc. Announces CEO Changes	12/23/12	CI
CytoDyn Inc. Announces Executive Changes	12/23/12	CI
CytoDyn Inc. Announces Executive Changes	25/23/25	CI
Transcript : CytoDyn Inc. - Special Call	12/23/12
CytoDyn Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2023	11/23/11	CI
CytoDyn Inc. announced that it has received $4.899 million in funding	03/23/03	CI
CytoDyn Inc. announced that it expects to receive $7.866 million in funding	13/23/13	CI
CytoDyn Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2022	10/23/10	CI
Transcript : CytoDyn Inc. - Special Call	29/22/29
MarketScreener's World Press Review: December 21, 2022	21/22/21

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. The Company is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions. Its core areas of clinical development are human immunodeficiency viruses (HIV), non-alcoholic steatohepatitis (NASH), and solid tumors in oncology. The areas of clinical focus in HIV are the lifting of the clinical hold, creation of a long-acting formulation of leronlimab and an HIV functional cure in using adenovirus vectors (AAV). In NASH, its focus is on the general population of those affected by NASH, and the subpopulation of patients with NASH and HIV. Regarding oncology, its focus remains on combination therapy for solid tumors.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CYTODYN INC.	-27.79%	15Cr
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	13TCr
REGENERON PHARMACEUTICALS, INC.	+23.61%	12TCr
ARGENX SE	+23.26%	2.79TCr
BIONTECH SE	-18.07%	2.1TCr
GENMAB A/S	-15.13%	1.69TCr
BEIGENE, LTD.	-14.81%	1.62TCr
NEUROCRINE BIOSCIENCES, INC.	+9.78%	1.48TCr
WUXI APPTEC CO., LTD.	-46.10%	1.48TCr
SAREPTA THERAPEUTICS, INC.	+52.34%	1.41TCr